RxDoctor Payments Data

Maribel Montano

Family · Houston, TXNPI 1821500497

Payments from drug & device makers

$2,023in general payments, 2019–2025

Across 100 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$475
  • Amgen$262
  • Novo Nordisk$218
  • Abbott$193
  • Lilly USA, LLC$171
  • Merck$128
  • plus $576 from 11 others

What the payments were for

  • Food & beverage$1,97197%
  • Education$513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,023 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$7,294
Medicare patients
20
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol86$105,593
TrulicityDulaglutide48$97,701
OzempicSemaglutide31$50,231
JardianceEmpagliflozin30$47,357
RybelsusSemaglutide16$34,261
EliquisApixaban20$16,775
VascepaIcosapent Ethyl11$12,000
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,371
Atorvastatin Calcium205$1,130
Gabapentin85$1,084
Nifedipine ErNifedipine25$661
Lisinopril110$577
Pioglitazone Hcl61$533
Famotidine29$509
Omeprazole35$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$475$105,59386 claims
Lilly USA, LLCTrulicity$171$97,70148 claims
Novo NordiskOzempic, Rybelsus$218$84,49147 claims
PfizerEliquis$70$16,77520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →